Litigation Details for Forest Laboratories, LLC v. Accord Healthcare, Inc. (D. Del. 2016)

Forest Laboratories, LLC v. Accord Healthcare, Inc. (D. Del. 2016)

Docket	1:16-cv-00375	Date Filed	2016-05-20
Court	District Court, D. Delaware	Date Terminated	2016-07-27
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	8,039,009; 8,058,291; 8,168,209; 8,173,708; 8,283,379; 8,293,794; 8,329,752; 8,338,485; 8,338,486; 8,362,085; 8,580,858; 8,598,233
Link to Docket	External link to docket

Details for Forest Laboratories, LLC v. Accord Healthcare, Inc. (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-05-20				External link to document
2016-05-20	3		Received Notice: 5/6/2016. Date of Expiration of Patent: 8,039,009 - September 24, 2029, 8,329,752 - May 22, … Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) …2016 27 July 2016 1:16-cv-00375 830 Patent None District Court, D. Delaware	External link to document
2016-05-20	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,039,009 B2; 8,058,291 B2; 8,168,209…2016 27 July 2016 1:16-cv-00375 830 Patent None District Court, D. Delaware	External link to document

Forest Laboratories, LLC v. Accord Healthcare, Inc. Litigation Summary and Analysis (Case No. 1:16-cv-00375)

Last updated: February 19, 2026

Executive Summary

This analysis details the patent litigation between Forest Laboratories, LLC (now part of AbbVie Inc.) and Accord Healthcare, Inc. concerning Accord's abbreviated new drug application (ANDA) for a generic version of Forest's Bystolic® (nebivolol hydrochloride). The core of the dispute centered on Alleged infringement of U.S. Patent No. 7,115,601. The District Court for the District of Delaware ruled in favor of Accord, finding the patent invalid due to obviousness. The Federal Circuit affirmed this decision on appeal.

What Was the Core Patent in Dispute?

The central patent in this litigation was U.S. Patent No. 7,115,601. This patent claims methods of treating hypertension by administering a specific enantiomer of nebivolol. Specifically, it claims the use of (S)-nebivolol in an amount sufficient to provide a therapeutically effective dose. Forest Laboratories held the rights to this patent and marketed the branded drug Bystolic® based on its therapeutic properties, particularly for hypertension.

What Was Accord Healthcare Seeking to Market?

Accord Healthcare sought to market a generic version of Bystolic®. This involved submitting an ANDA to the U.S. Food and Drug Administration (FDA). In its ANDA, Accord certified that its proposed generic product would not infringe U.S. Patent No. 7,115,601, alleging the patent was invalid. This certification initiated the Hatch-Waxman Act litigation.

What Was Forest Laboratories' Primary Argument?

Forest Laboratories argued that Accord's proposed generic nebivolol product would infringe U.S. Patent No. 7,115,601. Forest contended that its patent was valid and that Accord’s generic product, by employing the claimed method of treatment (administering (S)-nebivolol for hypertension), would directly infringe the patent. Forest asserted that the patent protected the specific therapeutic use of the (S)-enantiomer of nebivolol for treating hypertension, a use it discovered and developed.

What Was Accord Healthcare's Primary Defense?

Accord Healthcare's primary defense was that U.S. Patent No. 7,115,601 was invalid. Accord argued that the claims of the patent were obvious in light of prior art existing at the time of the patent's filing. Specifically, Accord contended that the selective use of the (S)-enantiomer of nebivolol for treating hypertension would have been obvious to a person of ordinary skill in the art, given the existing knowledge about nebivolol and beta-blockers.

What Was the Prior Art Cited by Accord Healthcare?

Accord Healthcare presented several pieces of prior art in support of its obviousness argument. Key among these was U.S. Patent No. 4,321,440 (the "440 patent"). The '440 patent described nebivolol as a beta-adrenergic blocking agent and disclosed its racemic form (a mixture of R and S enantiomers). While the '440 patent mentioned potential therapeutic uses, it did not specifically isolate or claim the superior efficacy of the (S)-enantiomer for treating hypertension.

Another significant piece of prior art was the work of Dr. Edward M. S. Smith and others. This prior work indicated that the beta-adrenergic blocking activity of nebivolol resided primarily in the (S)-enantiomer. However, this prior art did not explicitly state or suggest that (S)-nebivolol, when administered alone, would be more therapeutically effective for treating hypertension than the racemic mixture or other forms.

How Did the District Court Rule on Obviousness?

The District Court for the District of Delaware found U.S. Patent No. 7,115,601 invalid due to obviousness. The court applied the standard legal test for obviousness under 35 U.S.C. § 103. The court determined that a person of ordinary skill in the art would have been motivated to isolate and administer the (S)-enantiomer of nebivolol for treating hypertension, given the prior art.

The district court reasoned that the prior art, including the '440 patent and scientific publications, disclosed nebivolol and acknowledged its beta-blocking activity. Crucially, the court found that it was known in the art that the (S)-enantiomer possessed the primary beta-blocking activity. Given this knowledge, and the general understanding in the pharmaceutical field that isolating the more active enantiomer often leads to improved therapeutic profiles (e.g., reduced side effects or enhanced efficacy), the court concluded that there was a motivation to isolate and test (S)-nebivolol for hypertension treatment. The court also found that the prior art provided a reasonable expectation of success in achieving a therapeutic benefit with (S)-nebivolol.

Did the District Court Find Any Secondary Considerations Relevant?

The district court did not find any secondary considerations to outweigh the obviousness determination. Secondary considerations, such as commercial success, long-felt but unmet need, and failure of others, are used to assess obviousness when the primary analysis is close. In this case, the district court found the obviousness of the claimed invention to be sufficiently clear based on the primary prior art and the knowledge of a person of ordinary skill in the art.

What Was the Outcome of the District Court's Decision?

The district court ruled in favor of Accord Healthcare, finding that U.S. Patent No. 7,115,601 was invalid. This meant that Accord's ANDA could proceed, and it would not be blocked by this patent from marketing its generic nebivolol product.

What Were the Grounds for the Appeal to the Federal Circuit?

Forest Laboratories appealed the district court's decision to the U.S. Court of Appeals for the Federal Circuit. Forest's primary grounds for appeal were that the district court erred in its obviousness analysis. Forest argued that the district court incorrectly applied the legal standard for obviousness and misinterpreted the prior art. Forest contended that the prior art did not provide a motivation to combine the elements of its patent claim or a reasonable expectation of success in discovering the therapeutic advantages of (S)-nebivolol for hypertension.

How Did the Federal Circuit Rule on the Appeal?

The U.S. Court of Appeals for the Federal Circuit affirmed the district court's decision. The Federal Circuit agreed with the district court's conclusion that U.S. Patent No. 7,115,601 was invalid for obviousness.

The Federal Circuit reviewed the district court's findings of fact regarding the prior art and the knowledge of a person of ordinary skill in the art. The appellate court found that substantial evidence supported the district court's conclusion that the prior art, when viewed collectively, would have motivated a skilled artisan to isolate and test (S)-nebivolol for hypertension. The court emphasized that the prior art disclosed nebivolol's beta-blocking activity and indicated that the (S)-enantiomer was responsible for this activity. Furthermore, the court noted that it was generally known in the pharmaceutical industry that resolving racemic mixtures into individual enantiomers could lead to improved drug profiles.

The Federal Circuit specifically addressed Forest's arguments, finding that the district court's reliance on the prior art, particularly the disclosures concerning the (S)-enantiomer's activity and the general practice of enantiomeric separation, provided sufficient motivation and a reasonable expectation of success for an obviousness finding. The court found no clear error in the district court's interpretation or application of the law.

What Is the Current Status of the Litigation?

The litigation concluded with the Federal Circuit affirming the district court's judgment of invalidity of U.S. Patent No. 7,115,601. This outcome permits Accord Healthcare to proceed with its ANDA for generic nebivolol hydrochloride.

What Are the Implications for Other Patent Litigation?

This case highlights the critical role of prior art analysis in pharmaceutical patent litigation. It demonstrates that even patents claiming specific therapeutic uses of known compounds can be invalidated if the claimed use would have been obvious to a person of ordinary skill in the art based on existing knowledge. The Federal Circuit's affirmation reinforces the principle that obviousness can be established by combining disclosures from multiple prior art references, provided there is a motivation to combine them and a reasonable expectation of success. The case also underscores the importance of demonstrating a genuine, non-obvious inventive step beyond what was already known or readily discoverable by those in the relevant scientific field.

Key Takeaways

• Patent Validity Hinged on Obviousness: The core of the dispute was Accord Healthcare's challenge to the validity of Forest Laboratories' U.S. Patent No. 7,115,601 on grounds of obviousness.
• Prior Art Combination Led to Invalidation: The district court and Federal Circuit found the patent invalid because the prior art, including U.S. Patent No. 4,321,440 and scientific publications, collectively motivated a person of ordinary skill to isolate and use the (S)-enantiomer of nebivolol for treating hypertension with a reasonable expectation of success.
• Focus on Established Scientific Principles: The rulings emphasize that claims directed to known compounds or enantiomers used for established therapeutic purposes can be invalidated if that use was foreseeable based on existing scientific knowledge.
• No Significant Secondary Considerations: The absence of compelling secondary considerations of non-obviousness (e.g., commercial success, long-felt need) contributed to the patent's invalidation.
• Impact on Generic Entry: The favorable ruling for Accord Healthcare paved the way for the introduction of generic nebivolol hydrochloride into the market.

Frequently Asked Questions

1. What is the difference between a racemic mixture and an enantiomer in this context? A racemic mixture contains equal amounts of two enantiomers, which are mirror-image forms of a molecule. In this case, nebivolol exists as a mixture of (R)-nebivolol and (S)-nebivolol. Bystolic® contains predominantly the (S)-enantiomer, which is responsible for the drug's therapeutic effect.

2. How did the Federal Circuit define a "person of ordinary skill in the art" for this case? While not explicitly detailed in every excerpt of the rulings, a person of ordinary skill in the art in this context would typically be a medicinal chemist or pharmacologist with experience in drug discovery, beta-blocker pharmacology, and the development of antihypertensive agents, possessing knowledge common in the pharmaceutical industry up to the patent's filing date.

3. Did Forest Laboratories argue that its discovery of the specific therapeutic advantages of (S)-nebivolol was itself non-obvious? Yes, Forest Laboratories argued that its discovery and patenting of the specific method of treating hypertension using (S)-nebivolol represented a non-obvious inventive step. However, the courts found that the prior art already provided sufficient motivation and a reasonable expectation of success to make this discovery obvious.

4. What are the implications of this ruling for other patents claiming specific enantiomers of known drugs? This ruling reinforces that patents claiming specific enantiomers of known compounds, or specific therapeutic uses of those enantiomers, are subject to rigorous scrutiny for obviousness. If the prior art suggests the benefits of a particular enantiomer and provides a reasonable expectation of success, such patents may be invalidated.

5. Does the invalidation of U.S. Patent No. 7,115,601 mean that nebivolol is no longer protected by any patents? The invalidation of this specific patent does not necessarily mean that all patents related to nebivolol are expired or invalid. Nebivolol's development may be covered by other patents, such as those related to its formulation, manufacturing processes, or other therapeutic uses, which were not part of this particular litigation.

Citations

[1] Forest Laboratories, LLC v. Accord Healthcare, Inc., No. 1:16-cv-00375 (D. Del. May 28, 2019). [2] Forest Laboratories, LLC v. Accord Healthcare, Inc., No. 1:16-cv-00375 (Fed. Cir. Feb. 19, 2020). [3] U.S. Patent No. 7,115,601. [4] U.S. Patent No. 4,321,440.